-
Mashup Score: 5
Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing
Source: www.amazon.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 6Repurposing an Endogenous CRISPR-Cas System to Generate and Study Subtle Mutations in Bacteriophages | The CRISPR Journal - 15 day(s) ago
While bacteriophage applications benefit from effective phage engineering, selecting the desired genotype after subtle modifications remains challenging. Here, we describe a two-phase endogenous CRISPR-Cas-based phage engineering approach that enables selection of small defined edits in Pectobacterium carotovorum phage ZF40. We designed plasmids containing sequences homologous to ZF40 and a mini-CRISPR array. The plasmids allowed genome editing through homologous recombination and counter-selection against non-recombinant phage genomes using an endogenous type I-E CRISPR-Cas system. With this technique, we first deleted target genes and subsequently restored loci with modifications. This two-phase approach circumvented major challenges in subtle phage modifications, including inadequate sequence distinction for CRISPR-Cas counter-selection and the requirement of a protospacer-adjacent motif, limiting sequences that can be modified. Distinct 20-bp barcodes were incorporated through engi
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 8The CRISPR Journal | Vol 7, No 6 - 15 day(s) ago
The CRISPR Journal
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 2Mary Ann Liebert, Inc., publishers | News - 19 day(s) ago
News – Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in the most promising areas of biotechnology and regenerative medicine, biomedical research, clinical medicine and surgery, technology and engineering, law, integrative medicine, public health, and environmental studies.
Source: home.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 4CRISPR genome engineering - 1 month(s) ago
Join the conversation
Source: bsky.appCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 7Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative | The CRISPR Journal - 2 month(s) ago
Casgevy, the world’s first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of p
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 14Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects | The CRISPR Journal - 2 month(s) ago
Hematopoietic stem cells (HSCs) provide the body with a continuous supply of healthy, functional blood cells. In patients with hematopoietic malignancies, immunodeficiencies, lysosomal storage disorders, and hemoglobinopathies, therapeutic genome editing offers hope for corrective intervention, with even modest editing efficiencies likely to provide clinical benefit. Engineered white blood cells, such as T cells, can be applied therapeutically to address monogenic disorders of the immune system, HIV infection, or cancer. The versatility of CRISPR-based tools allows countless new medical interventions for diseases of the blood, and rapid ex vivo success has been demonstrated in hemoglobinopathies via transplantation of the patient’s HSCs following genome editing in a laboratory setting. Here we review recent advances in therapeutic genome editing of HSCs and T cells, focusing on the progress in ex vivo contexts, the promise of improved access via in vivo delivery, as well as the ongoing
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 57The CRISPR Journal | Vol 7, No 5 - 2 month(s) ago
The CRISPR Journal
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 1Modular Ontologies for Genetically Modified People and their Bioethical Implications - 4 month(s) ago
Participants in the long-running bioethical debate over human germline genetic modification (HGGM) tend to imagine future people abstractly and on the basis of conventionalized characteristics familiar from science fiction, such as intelligence, disease …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 20
The CRISPR Journal
Source: www.liebertpub.comCategories: General Medicine News, Future of MedicineTweet
Just in time for the holidays --> Executive Editor @KevinADavies' #CRISPR book EDITING HUMANITY is 50% off the second copy if you buy two at Amazon: https://t.co/TD8TLdzfTt https://t.co/MQK4coHDJ7